Scope of the Study
Meningococcal meningitis is a bacterial form of meningitis, a serious infection of the thin lining that surrounds the brain and spinal cord caused by Neisseria meningitidis, often referred to as meningococcus, a Gram-negative bacterium. It causes significant morbidity and mortality in children and young adults worldwide through an epidemic or sporadic meningitis and/or septicemia. According to the World Health Organization (WHO), meningococcal meningitis is observed worldwide but the highest burden of the disease is in the meningitis belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30 000 cases are still reported each year from that area. A range of antibiotics are used for the treatment of meningitis such as penicillin, ampicillin and ceftriaxone.
The market study is being classified by Type (Penicillin, Ampicillin and Ceftriaxone) and major geographies with country level break-up.
Beijing Minhai Biotechnology Co Ltd (China), GlaxoSmithKline Plc (United Kingdom), ImmunoBiology Ltd (United Kingdom), JN-International Medical Corp (United States), MGB Biopharma Ltd (United Kingdom), Panacea Biotec Ltd (India), Pfizer Inc (United States), Sanofi Pasteur SA (France), Serum Institute of India Ltd (India) and Wellstat Therapeutics Corporation (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Biological E Ltd (India) and China National Pharmaceutical Group Corp (China).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Neisseria meningitidis Infections Drug market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Neisseria meningitidis Infections Drug market by Type, Application and Region.
On the basis of geography, the market of Neisseria meningitidis Infections Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Meningococcal meningitis
- Increased Number of Hospitals and Clinics
- Growing Focus on Preventive Health Care
- Fluctuations in the Raw Material Prices
- Increasing Number of Regulatory Approvals
- Growth in the Health Care Industry
- Stringent Rules and Regulations of the Governments
Key Target AudienceNeisseria meningitidis Infections Drug Manufacturers, Raw Material Suppliers, Distributors and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase